Eun Yang
Stock Analyst at Jefferies
(0.53)
# 4,188
Out of 5,136 analysts
35
Total ratings
35%
Success rate
-24.21%
Average return
Main Sectors:
Stocks Rated by Eun Yang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GBIO Generation Bio Co. | Downgrades: Hold | $11 → $5 | $5.65 | -11.50% | 1 | Dec 16, 2025 | |
| RIGL Rigel Pharmaceuticals | Upgrades: Buy | $23 → $42 | $39.12 | +7.36% | 1 | Nov 5, 2025 | |
| ATXS Astria Therapeutics | Downgrades: Hold | $30 → $13 | $12.54 | +3.67% | 3 | Oct 14, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $315 → $432 | $475.73 | -9.19% | 8 | Sep 23, 2024 | |
| TSHA Taysha Gene Therapies | Assumes: Buy | $2 → $8 | $5.04 | +58.73% | 2 | May 14, 2024 | |
| RLYB Rallybio | Downgrades: Hold | $7 → $1.5 | $0.69 | +118.88% | 2 | Feb 7, 2024 | |
| BBIO BridgeBio Pharma | Downgrades: Hold | $24 → $33 | $77.90 | -57.64% | 1 | Jul 18, 2023 | |
| BMEA Biomea Fusion | Downgrades: Hold | $36 → $28 | $1.62 | +1,628.40% | 2 | Jun 26, 2023 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $27 | $26.05 | +3.65% | 1 | Mar 29, 2023 | |
| GNSS Genasys | Maintains: Outperform | $6 → $7 | $2.25 | +211.11% | 1 | Feb 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $4.31 | +480.05% | 1 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $105,000 → $15,000 | $3.33 | +450,350.45% | 1 | Sep 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $1.99 | +1,156.28% | 1 | Nov 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $22.09 | +58.44% | 1 | Jun 22, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $200 → $220 | $328.97 | -33.12% | 3 | Jul 27, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $310 | $169.31 | +83.10% | 3 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Hold | $80 | $124.07 | -35.52% | 3 | Jul 11, 2017 |
Generation Bio Co.
Dec 16, 2025
Downgrades: Hold
Price Target: $11 → $5
Current: $5.65
Upside: -11.50%
Rigel Pharmaceuticals
Nov 5, 2025
Upgrades: Buy
Price Target: $23 → $42
Current: $39.12
Upside: +7.36%
Astria Therapeutics
Oct 14, 2025
Downgrades: Hold
Price Target: $30 → $13
Current: $12.54
Upside: +3.67%
United Therapeutics
Sep 23, 2024
Maintains: Buy
Price Target: $315 → $432
Current: $475.73
Upside: -9.19%
Taysha Gene Therapies
May 14, 2024
Assumes: Buy
Price Target: $2 → $8
Current: $5.04
Upside: +58.73%
Rallybio
Feb 7, 2024
Downgrades: Hold
Price Target: $7 → $1.5
Current: $0.69
Upside: +118.88%
BridgeBio Pharma
Jul 18, 2023
Downgrades: Hold
Price Target: $24 → $33
Current: $77.90
Upside: -57.64%
Biomea Fusion
Jun 26, 2023
Downgrades: Hold
Price Target: $36 → $28
Current: $1.62
Upside: +1,628.40%
Enliven Therapeutics
Mar 29, 2023
Initiates: Buy
Price Target: $27
Current: $26.05
Upside: +3.65%
Genasys
Feb 10, 2023
Maintains: Outperform
Price Target: $6 → $7
Current: $2.25
Upside: +211.11%
Nov 14, 2022
Initiates: Buy
Price Target: $25
Current: $4.31
Upside: +480.05%
Sep 22, 2022
Maintains: Buy
Price Target: $105,000 → $15,000
Current: $3.33
Upside: +450,350.45%
Nov 2, 2021
Initiates: Buy
Price Target: $25
Current: $1.99
Upside: +1,156.28%
Jun 22, 2021
Initiates: Buy
Price Target: $35
Current: $22.09
Upside: +58.44%
Jul 27, 2018
Maintains: Buy
Price Target: $200 → $220
Current: $328.97
Upside: -33.12%
Jul 11, 2017
Assumes: Hold
Price Target: $310
Current: $169.31
Upside: +83.10%
Jul 11, 2017
Assumes: Hold
Price Target: $80
Current: $124.07
Upside: -35.52%